Ligand Pharmaceuticals Incorporated – Product Pipeline Review – Q4 2010

Date: December 1, 2010
Pages: 93
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: LE72CA6C30CEN
Leaflet:

Download PDF Leaflet

Ligand Pharmaceuticals Incorporated – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Ligand Pharmaceuticals Incorporated – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Ligand Pharmaceuticals Incorporated – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Ligand Pharmaceuticals Incorporated human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Ligand Pharmaceuticals Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Ligand Pharmaceuticals Incorporated’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Ligand Pharmaceuticals Incorporated’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Ligand Pharmaceuticals Incorporated in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Ligand Pharmaceuticals Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Ligand Pharmaceuticals Incorporated.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Ligand Pharmaceuticals Incorporated and identify potential opportunities in those areas.
Ligand Pharmaceuticals Incorporated Snapshot
Ligand Pharmaceuticals Incorporated Overview
Key Information
Key Facts
Ligand Pharmaceuticals Incorporated – Research and Development Overview
Key Therapeutic Areas
Ligand Pharmaceuticals Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Ligand Pharmaceuticals Incorporated – Pipeline Products Glance
Ligand Pharmaceuticals Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ligand Pharmaceuticals Incorporated–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Ligand Pharmaceuticals Incorporated – Drug Profiles
Aplindore
  Product Description
  Mechanism of Action
  R&D Progress
MB07133
  Product Description
  Mechanism of Action
  R&D Progress
MB07803
  Product Description
  Mechanism of Action
  R&D Progress
MB07811
  Product Description
  Mechanism of Action
  R&D Progress
PS433540
  Product Description
  Mechanism of Action
  R&D Progress
Targretin
  Product Description
  Mechanism of Action
  R&D Progress
LGD-4033
  Product Description
  Mechanism of Action
  R&D Progress
PS248288
  Product Description
  Mechanism of Action
  R&D Progress
PS386113
  Product Description
  Mechanism of Action
  R&D Progress
PS948115
  Product Description
  Mechanism of Action
  R&D Progress
Selective Glucocorticoid Receptor Modulator
  Product Description
  Mechanism of Action
  R&D Progress
BACE Inhibitor
  Product Description
  Mechanism of Action
  R&D Progress
EPO Receptor Agonist
  Product Description
  Mechanism of Action
  R&D Progress
Glucagon Receptor Antagonist Program
  Product Description
  Mechanism of Action
  R&D Progress
H3 Antagonist Program
  Product Description
  Mechanism of Action
  R&D Progress
LGD 3303
  Product Description
  Mechanism of Action
  R&D Progress
MB11262
  Product Description
  Mechanism of Action
  R&D Progress
PS031291
  Product Description
  Mechanism of Action
  R&D Progress
TR Beta Agonist
  Product Description
  Mechanism of Action
  R&D Progress
MB07100
  Product Description
  Mechanism of Action
  R&D Progress
Ligand Pharmaceuticals Incorporated – Pipeline Analysis
Ligand Pharmaceuticals Incorporated – Pipeline Products by Therapeutic Class
Ligand Pharmaceuticals Incorporated Pipeline Products By Target
Ligand Pharmaceuticals Incorporated – Pipeline Products by Route of Administration
Ligand Pharmaceuticals Incorporated – Pipeline Products by Molecule Type
Ligand Pharmaceuticals Incorporated - Dormant Projects
Ligand Pharmaceuticals Incorporated - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NGD 2000-1
NGD 94-1
NGD 97-1
NGD-4715
Ligand Pharmaceuticals Incorporated – Company Statement
Ligand Pharmaceuticals Incorporated – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 04, 2010: Ligand Announces Positive Preclinical Data On Small Molecule Erythropoietin Receptor Agonists
Mar 29, 2010: Ligand Presents First-in-Human Phase I Data On Lead SARM Molecule LGD-4033 At International Congress Of Endocrinology
Mar 29, 2010: Ligand Presents First-in-Human Phase I Data On Lead SARM Molecule LGD-4033 At International Congress Of Endocrinology
Mar 29, 2010: Ligand Presents First-in-Human Phase I Data On Lead SARM Molecule LGD-4033 At International Congress Of Endocrinology
Mar 29, 2010: Ligand Presents First-in-Human Phase I Data On Lead SARM Molecule LGD-4033 At International Congress Of Endocrinology
Mar 29, 2010: Ligand Presents First-in-Human Phase I Data On Lead SARM Molecule LGD-4033 At International Congress Of Endocrinology
Jan 28, 2010: Ligand Pharmaceuticals acquires Metabasis Therapeutics
Dec 23, 2009: Ligand Completes Neurogen Acquisition
Nov 20, 2009: Ligand Presents New Preclinical Data On Its Lead SARM Molecule LGD-4033 At The Gerontological Society Of America Annual Meeting
Jun 17, 2009: Ligand Initiates Clinical Trial With The Selective Androgen Receptor Modulator LGD-4033, A Potential Treatment Of Muscle And Bone Disorders
Financial Deals Landscape
Ligand Pharmaceuticals Incorporated, Deals Summary, 2004 to 2010
Ligand Pharmaceuticals Incorporated Detailed Deal Summary
Asset Purchase
King Pharmaceuticals Acquires AVINZA From Ligand Pharmaceuticals
Acquisition
Ligand Pharmaceuticals Acquires Metabasis Therapeutics
Ligand Pharmaceuticals Completes Acquisition Of Neurogen
Ligand Pharmaceuticals Acquires Pharmacopeia
Ligand Extends Its Research Agreement With Pfizer
Ligand Pharmaceuticals Enters Into An Amended Agreement With GlaxoSmithKline
Pharmacopeia Enters Into A Co-Development Agreement With Cephalon
GlaxoSmithKline Enters Into Drug Development Agreement With Pharmacopeia
Pharmacopeia Drug Discovery Expands Its Agreement With Neurocrine Biosciences
Biovitrum Enters Into Drug Discovery Collaboration Agreement With Pharmacopeia
Taiho Pharmaceutical Enters Into Co-Development Agreement With Ligand Pharmaceuticals
Pharmacopeia Enters Into Co-Development Agreement With Taiho Pharmaceutical
Licensing Agreements
Ligand Pharmaceuticals Amends Licensing Agreement With Exelixis
Glycomed Enters Into Licensing Agreement With ParinGenix
Ligand Pharmaceuticals Enters Into Agreement With Trevena
Ligand Pharmaceuticals Enters Into Licensing Agreement With GlaxoSmithKline
Pharmacopeia Enters Into Licensing Agreement With Bristol-Myers Squibb
Pharmacopeia Enters Into Licensing Agreement With Wyeth
Pharmacopeia Enters Into Licensing Agreement With Bristol-Myers
Pharmacopeia Enters Into Licensing Agreement With Allergan
Ligand And Organon Mutually Terminate Collaboration And License Agreement
Ligand Pharmaceuticals Terminates Licensing Agreement With Salk Institute For Biological Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Ligand Pharmaceuticals Incorporated – Pipeline by Therapy Area and Indication, 2010
Ligand Pharmaceuticals Incorporated – Pipeline by Stage of Development, 2010
Ligand Pharmaceuticals Incorporated – Monotherapy Products in Pipeline, 2010
Ligand Pharmaceuticals Incorporated - Phase II, 2010
Ligand Pharmaceuticals Incorporated - Phase I, 2010
Ligand Pharmaceuticals Incorporated - Pipeline By Therapeutic Class, 2010
Ligand Pharmaceuticals Incorporated - Pipeline By Target, 2010
Ligand Pharmaceuticals Incorporated – Pipeline By Route of Administration, 2010
Ligand Pharmaceuticals Incorporated – Pipeline By Molecule Type, 2010
Ligand Pharmaceuticals Incorporated - Dormant Developmental Projects, 2010
Ligand Pharmaceuticals Incorporated - Discontinued Pipeline Products, 2010
Ligand Pharmaceuticals Incorporated, Subsidiaries
Ligand Pharmaceuticals Incorporated, Deals Summary, 2004 to 2010
Ligand Pharmaceuticals Incorporated, Deals Summary, 2004 to 2010 61

LIST OF FIGURES

Ligand Pharmaceuticals Incorporated – Pipeline by Therapy Area and Indication, 2010
Ligand Pharmaceuticals Incorporated – Pipeline by Stage of Development, 2010
Ligand Pharmaceuticals Incorporated – Monotherapy Products in Pipeline, 2010
Ligand Pharmaceuticals Incorporated – Pipeline By Therapeutic Class, 2010
Ligand Pharmaceuticals Incorporated - Pipeline By Target, 2010
Ligand Pharmaceuticals Incorporated – Pipeline By Route of Administration, 2010
Ligand Pharmaceuticals Incorporated – Pipeline By Molecule Type, 2010 43

Ask Your Question

Ligand Pharmaceuticals Incorporated – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: